Actinium Pharmaceuticals, Inc.

actiniumpharma.com

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) (NYSE MKT: ATNM) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

TELIX TO EXPAND LATE-STAGE UROLOGIC PIPELINE WITH ACQUISITION OF LIGHTPOINT MEDICAL

PRNewswire | June 22, 2023

news image

Telix Pharmaceuticals Limited announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals. SENSEI is an ultra-miniature robotic gamma probe for intracavital use that is able to provide radiopharmaceutical-based surgical guidance ("radio-guided surgery") by enabl...

Read More

Cell and Gene Therapy, Industrial Impact

GI CELL ENTERS AGREEMENT WITH OPTIEUM BIOTECHNOLOGIES

GI CELL | December 13, 2022

news image

GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematological tumor targets generated through Optieum Biotechnologies’ Eumbody System™. GI CELL will carry out feasibility studies and be responsible for further development and commercialization of the CAR-NK cell products if the company exercises an option. ...

Read More

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

news image

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More

Medical

HEALTHPARTNERS, HELIX PARTNER TO CREATE DNA TESTING PROGRAM THAT HELPS FAMILIES BETTER UNDERSTAND THEIR GENETIC HEALTH

Helix | March 09, 2022

news image

HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states. The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk ea...

Read More
news image

Industrial Impact

TELIX TO EXPAND LATE-STAGE UROLOGIC PIPELINE WITH ACQUISITION OF LIGHTPOINT MEDICAL

PRNewswire | June 22, 2023

Telix Pharmaceuticals Limited announces it has entered into an agreement to acquire Lightpoint Medical and its SENSEI® radio-guided surgery business. Lightpoint Medical is a United Kingdom-based medical device company specialising in the intra-operative detection of targeted radiopharmaceuticals. SENSEI is an ultra-miniature robotic gamma probe for intracavital use that is able to provide radiopharmaceutical-based surgical guidance ("radio-guided surgery") by enabl...

Read More
news image

Cell and Gene Therapy, Industrial Impact

GI CELL ENTERS AGREEMENT WITH OPTIEUM BIOTECHNOLOGIES

GI CELL | December 13, 2022

GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. Under the agreement, Optieum Biotechnologies will provide GI CELL with scFv antibodies directed against hematological tumor targets generated through Optieum Biotechnologies’ Eumbody System™. GI CELL will carry out feasibility studies and be responsible for further development and commercialization of the CAR-NK cell products if the company exercises an option. ...

Read More
news image

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More
news image

Medical

HEALTHPARTNERS, HELIX PARTNER TO CREATE DNA TESTING PROGRAM THAT HELPS FAMILIES BETTER UNDERSTAND THEIR GENETIC HEALTH

Helix | March 09, 2022

HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states. The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk ea...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us